Moomoo AI 已提取核心信息
On January 30, 2024, Pfizer Inc. released its financial results for the fourth quarter and the full year of 2023. The announcement was made through a press release, which is now available as Exhibit 99. This information, including the press release, is furnished under Item 2.02 - Results of Operations and Financial Condition of the Form 8-K report filed with the SEC. However, it is clarified that the furnished information is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. Furthermore, the information is not to be incorporated by reference into any of Pfizer's filings under the Exchange Act or the Securities Act of 1933, except as explicitly stated in such filings.
On January 30, 2024, Pfizer Inc. released its financial results for the fourth quarter and the full year of 2023. The announcement was made through a press release, which is now available as Exhibit 99. This information, including the press release, is furnished under Item 2.02 - Results of Operations and Financial Condition of the Form 8-K report filed with the SEC. However, it is clarified that the furnished information is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. Furthermore, the information is not to be incorporated by reference into any of Pfizer's filings under the Exchange Act or the Securities Act of 1933, except as explicitly stated in such filings.
2024年1月30日，辉瑞公司发布了第四季度和2023年全年的财务业绩。该公告是通过新闻稿发布的，该新闻稿现已作为附录99发布。这些信息，包括新闻稿，是在向美国证券交易委员会提交的8-K表报告的第2.02项——经营业绩和财务状况下提供的。但是，澄清的是，就1934年《证券交易法》第18条而言，所提供的信息不被视为 “已提交”，也不受该节规定的责任的约束。此外，除非此类文件中明确规定，否则不得以引用方式将这些信息纳入辉瑞根据1933年《交易法》或《证券法》提交的任何文件中。
2024年1月30日，辉瑞公司发布了第四季度和2023年全年的财务业绩。该公告是通过新闻稿发布的，该新闻稿现已作为附录99发布。这些信息，包括新闻稿，是在向美国证券交易委员会提交的8-K表报告的第2.02项——经营业绩和财务状况下提供的。但是，澄清的是，就1934年《证券交易法》第18条而言，所提供的信息不被视为 “已提交”，也不受该节规定的责任的约束。此外，除非此类文件中明确规定，否则不得以引用方式将这些信息纳入辉瑞根据1933年《交易法》或《证券法》提交的任何文件中。
有用
没用